Phaseline

Targets › CEA

CEA (Cell adhesion molecule CEACAM5): drug programs, companies and trials

8 programs from 6 companies in 12 trials: 8 Phase 1, 3 Phase 2, 1 Phase 3; Oncology; next expected readout Nov 2026.

Cell surface glycoprotein that plays a role in cell adhesion, intracellular signaling and tumor progression. Mediates homophilic and heterophilic cell adhesion with other carcinoembryonic antigen-related cell adhesion molecules, such as CEACAM6. (UniProt, P06731)

Open in Phaseline: the race on CEA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
OSE ImmunotherapeuticsOSE2101
peptidic cancer vaccine with nine HLA-A2-restricted epitopes targeting tumor-associated an
TP53, ERBB2, CEA, MAGEA2, MAGEA3Phase 3Patients With Non-Small Cell Lung Cancer; Solid Advanced TumorDec 2027
National Cancer Institute (NCI)Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5
Therapeutic cancer vaccine expressing CEA, MUC1, and Brachyury tumor-associated antigens
CEA, MUC1, TBXTPhase 2Colorectal CarcinomaJul 2027
Fondazione Ricerca TraslazionaleTedopi
Cancer vaccine inducing cytotoxic T-lymphocytes against tumor-associated antigens (CEA, p5
CEA, TP53, ERBB2, MAGE2, MAGE3Phase 2Metastatic Non Small Cell Lung CancerSep 2027
National Cancer Institute (NCI)Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform
Adenoviral-based cancer vaccine targeting CEA, Brachyury and MUC1
CEA, BRACHYURY, MUC1, KLK3, TBXTPhase 2Adenocarcinoma; Metastatic Colorectal CancerOct 2027
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairCEA protein antigen plus BCG Vaccine Mix
CEA antigen with trained immunity via BCG; APCs process CEA antigen into peptide fragments
CEAPhase 1Rectal CancerNov 2026
Beijing BiotechEB-DUO-CAR-NK-CEA/GCC
Dual-target CAR-NK cell therapy targeting CEA and GUCY2C (or CEA and HER2, or GUCY2C and H
CEACAM5, GUCY2C, ERBB2, CEA, HER2, IL15Phase 1Colorectal Cancer; Colorectal Cancer MetastaticMar 2027
National Cancer Institute (NCI)Falimarev (Fowlpox-CEA-MUC-1-TRICOM)
Recombinant fowlpox virus expressing CEA and MUC-1 tumor-associated antigens with TRICOM c
CEA, MUC1Phase 1Locally Advanced Pancreatic AdenocarcinomaApr 2027
City of Hope Medical CenterM5A-IL2 immunocytokine
CEA-targeting immunocytokine; fuses M5A anti-CEA antibody to IL-2 cytokine to activate imm
CEAPhase 1Breast CarcinomaMar 2029

Conditions

Locally Advanced Pancreatic Adenocarcinoma (2) Adenocarcinoma (1) Metastatic Colorectal Cancer (1) Patients With Non-Small Cell Lung Cancer (1) Solid Advanced Tumor (1) Colorectal Cancer (1) Colorectal Cancer Metastatic (1) Rectal Cancer (1) Metastatic Non Small Cell Lung Cancer (1) Colorectal Carcinoma (1) Breast Carcinoma (1)

Modalities

mixed (4), small molecule (2), protein or peptide (1), other (1)

Companies

National Cancer Institute (NCI) (3) OSE Immunotherapeutics (1) Beijing Biotech (1) Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair (1) Fondazione Ricerca Traslazionale (1) City of Hope Medical Center (1)

Related targets

MUC1 (3) ERBB2 (3) TBXT (2) TP53 (2) BRACHYURY (1) KLK3 (1) MAGEA2 (1) MAGEA3 (1) CEACAM5 (1) GUCY2C (1) HER2 (1) IL15 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.